Paulette received a regulatory letter from the Shenzhen Stock Exchange. The company committed the following irregularities: some medical device trading business revenue confirmation was not accurate; some sales returns did not reduce revenue in a timely manner; individual projects under construction were not transferred to fixed assets in a timely manner and depreciated; there was no reasonable basis for predicting indicators during goodwill impairment tests for some subsidiaries; and the company's internal controls were not standardized. The above acts are in violation of relevant regulations. As the chairman and president of the company, and Xu Wei, as the company's financial director, failed to perform her duties with due diligence and due diligence, and violated relevant regulations.

Paulette received a regulatory letter from the Shenzhen Stock Exchange. The company committed the following irregularities: some medical device trading business revenue confirmation was not accurate; some sales returns did not reduce revenue in a timely manner; individual projects under construction were not transferred to fixed assets in a timely manner and depreciated; there was no reasonable basis for predicting indicators during goodwill impairment tests for some subsidiaries; and the company's internal controls were not standardized. The above acts are in violation of relevant regulations. As the chairman and president of the company, and Xu Wei, as the company's financial director, failed to perform her duties with due diligence and due diligence, and violated relevant regulations.